<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308854</url>
  </required_header>
  <id_info>
    <org_study_id>AK 03</org_study_id>
    <secondary_id>EudraCT Number 2005-003555-13</secondary_id>
    <nct_id>NCT00308854</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AK</brief_title>
  <official_title>PD P 506 A or Its Placebo in Combination With Red Light for Photodynamic Therapy of Mild to Moderate Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>photonamic GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>photonamic GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether PD P 506 A-PDT is effective in treating mild&#xD;
      to moderate AK lesions located on the head.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actinic keratosis (AK) is a pre-cancerous skin abnormality usually caused by sun exposure.&#xD;
      Actinic keratoses occur most commonly in fair skin, especially in the elderly. They mainly&#xD;
      occur in sun-exposed skin areas like head and hands. It is standard of care to remove AK when&#xD;
      diagnosed, which can be achieved by either physical ablation, chemotherapeutic agents or&#xD;
      photodynamic therapy (PDT). A direct comparison versus placebo which is necessary for the&#xD;
      exact quantification of the effect of PD P 506 A has not yet been performed and is subject of&#xD;
      this study protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical clearance rate (CCR) of treated actinic keratosis lesions 12 weeks after PDT</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CCR on patient basis 12 weeks, 6, 9 and 12 months after PDT</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCR of treated actinic keratosis lesions 6, 9 and 12 months after PDT</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events/reactions and local reactions during application of the study medication as well as during and after study therapy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction and independent cosmetic rating of the cleared study lesions by patient and investigator in case of successful clearance and no recurrence of the lesion</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PD P 506 A-PDT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic Therapy</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Caucasian patients&#xD;
&#xD;
          -  Diagnosis of actinic keratosis (AK) with at least three locally separated lesions&#xD;
             located on head and/or face (hairless areas)&#xD;
&#xD;
          -  Selected AK study lesions have clearly defined margins and are mild to moderate&#xD;
&#xD;
          -  The distance between the study lesion borders is &gt; 1.0 cm&#xD;
&#xD;
          -  Maximum diameter of each study lesion is 1.8 cm&#xD;
&#xD;
          -  Skin sun sensitivity type I to IV according to Fitzpatrick&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PDT Non-responder&#xD;
&#xD;
          -  Pre-treatment of the AK lesions eligible for study procedures with pharmaceuticals&#xD;
             approved for the treatment of AK during the 4 weeks preceding PDT&#xD;
&#xD;
          -  Pre-treatment of the AK lesions eligible for study procedures during the 2 weeks&#xD;
             preceding PDT with keratolytic agents e.g. TCA, urea or salicylic acid containing&#xD;
             formulations&#xD;
&#xD;
          -  Pre-treatment with hypericin during the 2 weeks preceding PDT&#xD;
&#xD;
          -  Treatment with systemic retinoids during the 3 months preceding PDT&#xD;
&#xD;
          -  Treatment with cytostatics or radiation during the 3 months preceding PDT&#xD;
&#xD;
          -  Female patients of childbearing potential&#xD;
&#xD;
          -  Patients with clinically relevant suppression of the immune system&#xD;
&#xD;
          -  Diagnosis of Porphyria&#xD;
&#xD;
          -  Skin diseases that might interfere with response evaluation of study PDT&#xD;
&#xD;
          -  Skin sun sensitivity type V or VI according to Fitzpatrick&#xD;
&#xD;
          -  Known intolerance to one or more of the ingredients of the study medication&#xD;
&#xD;
          -  Dementia or psychic condition that might interfere with the ability to understand the&#xD;
             study and thus give a written informed consent&#xD;
&#xD;
          -  Simultaneous participation in another clinical study or participation in another&#xD;
             clinical study in the 30 days directly preceding inclusion&#xD;
&#xD;
          -  Suspected lack of compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Hauschild, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian-Albrechts-Universit√§t zu Kiel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Dr. Popp Dipl.-Med. Weber</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologisches Zentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Professor Dr. Uwe Reinhold</name>
      <address>
        <city>Bonn</city>
        <zip>53225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum Dermatologie und Venerologie, Klinikum und Fachbereich Medizin</name>
      <address>
        <city>Frankfurt a.M.</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SciDerm</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologisches Ambulatorium Hamburg-Alstertal</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Scholz/Sebastian/Schilling</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2006</study_first_posted>
  <last_update_submitted>April 10, 2008</last_update_submitted>
  <last_update_submitted_qc>April 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <keyword>AK</keyword>
  <keyword>PDT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

